Sertoli cells (SC) play a critical role in the maintenance of the immunoprivileged environment of the testis. We hypothesized that preengrafting SC would allow one to develop a vascularized immunoprivileged ectopic site that provides protection for mouse islet allografts. SC, prepared from 9-day Balb/c mice, were transplanted under the kidney capsule in adult Balb/c mice. After SC engraftment (ϳ30 days), mice were rendered diabetic and subsequently implanted with Balb/c or CBA/J islets directly adjacent to the established SC grafts. Preengrafted SC (5.7 ± 0.2 × 10 6 ) had no adverse effect on syngeneic islet graft function. When allogeneic islets were transplanted into the immunoprivileged ectopic site created by preengrafting 6.4 ± 0.3 × 10 6 SC, mean graft survival was slightly prolonged (32.4 ± 6.0 days) compared with control mice that received allogeneic islets alone (16.3 ± 1.5 days; p = 0.329). In contrast, when 4.8 ± 0.4 × 10 6 SC were preengrafted, islet allograft survival was significantly prolonged (66.1 ± 9.8 days; p = 0.001). Four of eight mice, preimplanted with 4.8 ± 0.4 × 10 6 SC, remained normoglycemic throughout the follow-up period (83.8 ± 8.6 days) and returned to a diabetic state only when the kidneys bearing the composite grafts were removed. Transplantation of islets into an immunoprivileged ectopic site created by preengrafting SC did not affect islet function and, moreover, provided a means of developing an immunopriveliged ectopic site that permits prolonged islet allograft survival without systemic immunosuppression.
INTRODUCTION
ing a testicular-like environment that is well vascularized and thereby capable of supporting islet engraftment Islet transplantation has now become a viable option and to ensure immunoprotection. In particular, the abilfor treating patients with type I diabetes (8) . Because ity to create an immunopriveliged site by preengrafting there is currently a requirement for chronic immunosup-Sertoli cells could potentially permit the colocalization presion to prevent human islet allograft destruction, few of islets and Sertoli cells in sites such as the subcutanepatients with type I diabetes, especially young juvenile ous space or a surgically created omental pouch. The diabetics, are candidates for this procedure. To potenaim of the present study was first to study whether a tially overcome this obstacle, a novel cellular therapeutesticular-like site could be created by preengrafting Sertic approach has emerged to engraft and protect islets toli cells under the kidney capsule and, moreover, examfrom allograft (3) and xenograft (11) rejection as well ine whether this site supports islet engraftment and preas autoimmune destruction (4, 9) . This approach employs vents rejection of allogeneic islets. the cotransplantation of islets with immunoprotective MATERIALS AND METHODS Sertoli cells under the renal subcapsular space. Because it has been known that the testis is an immunoprivileged Male Balb/c (University of Alberta) and CBA/J mice (Jackson Laboratories, Bar Harbor, ME), age 8-10 site (1,7) and because we routinely observe that when Sertoli cells are cotransplanted with islets they reorga-weeks, were used as islet donors and male Balb/c mice, age 6-11 days, were used as Sertoli cells donors. Recip-nize into tubule structures closely resembling the architecture of the testis (9), it is therefore probable that the ients were male Balb/c mice, age 8-16 weeks. Sertoli cells were prepared and cultured as previously described morphological organization of Sertoli cells within the testis is important for providing an immunoprotective (3,4). After 48-72-h culture, a known mass of Sertoli cells was aspirated into polyethylene tubing (PE-50), environment. Furthermore, it also raises the possibility to preengraft Sertoli cells with the purpose of develop-pelleted by centrifugation, and then implanted under the 548 KIN ET AL.
left renal subcapsular space of halothane-anesthetized after incubation with 0.01 M HCl, sections were then blocked with 20% normal goat serum (15 min) and incu-Balb/c mice (n = 7 for syngeneic and n = 26 for allogeneic transplants). At ϳ30 days posttransplant, these bated with guinea pig anti-insulin primary antibody for 30 min. Sections were then incubated with biotinylated mice were rendered diabetic by IP injection of streptozotocin (Sigma, St. Louis, MO) at a dose of 275 mg/kg goat anti-guinea pig secondary antibody (20 min) followed by alkaline phosphatase with Vector red as the body weight. Diabetes was confirmed by the presence of hyperglycemia and only those mice with two consec-chromagen, to stain β-cells red. All sections were subsequently counterstained with hematoxylin. utive nonfasting blood glucose levels exceeding 20 mM were used as recipients. Islets were then isolated by col-Data are expressed as means ± SEM of n independent experiments. Statistical significance of differences be-lagenase (Sigma, Type V) digestion, dextran gradient purification, and subsequently cultured 24-72 h before tween two independent groups was calculated with the unpaired Student's t-test. For multiple comparisons a transplantation (4).
Under halothane anesthesia, 500 islets were trans-one-way ANOVA was used. When significance was observed, comparisons between groups were made using planted directly adjacent to the established Sertoli cell graft in diabetic mice. Allogeneic controls included dia-the Scheffe's F-test. A value of p < 0.05 was considered significant. betic mice without Sertoli cell preengraftment. After islet transplantation, blood was withdrawn from the tail RESULTS vein every 2 days to determine nonfasting blood glucose levels (Fast Take; LifeScan, Canada). Graft rejection Considerable growth as well as extensive neovascularization of the Sertoli cell grafts was macroscopically was defined as two successive blood glucose levels >11 mM. Mice implanted with syngeneic islets adjacent to evident when the grafts were exposed immediately prior to islet implantation (43.0 ± 3.0 days posttransplant). the Sertoli cell graft underwent an oral glucose tolerance test (OGTT) 4 weeks after islet transplantation. Dextrose
Immunohistochemical localization of GATA-4-positive Sertoli cells revealed that the Sertoli cells were arranged (3 mg/g body weight) was gavaged into mice fasted for 3 h. Blood samples for glucose determination were ob-in tubule structures similar to seminiferous tubules in the native testis ( Fig. 2A, B) . A small percentage of tained at 0, 15, 30, 60, and 120 min following glucose administration. Two days after OGTT, mice underwent GATA-4-positive Sertoli cells was also localized outside of the tubules and, furthermore, the diameter of the ma-a nephrectomy of the graft-bearing kidney to determine cellular insulin content of the graft (5), as well as con-jority of tubules was larger than that found in the native testis. To first investigate whether preengrafted Sertoli firm a return to hyperglycemia. In recipients of allogeneic islets, grafts were examined at various times from cells can exert an adverse effect on islet function, syngeneic islets were transplanted directly adjacent to this im-euglycemic animals for histological assessment.
For histology, grafts were immersed in Z-fix (Davis munoprivileged ectopic site initially created with 5.7 ± 0.2 × 10 6 Sertoli cells ( Fig. 1A ). All animals (n = 7) Diagnostics Inc., Mississauga, ONT), embedded in paraffin, sectioned, and single stained for insulin, GATA-4, preengrafted with Sertoli cells and subsequently transplanted with syngeneic islets achieved euglycemia smooth muscle alpha actin, or double stained for insulin and GATA-4. GATA-4 is a zinc finger protein that within 2 days after transplantation. This metabolic state was maintained over a 30-day follow-up period; when binds the nuclei of Sertoli cells and is therefore utilized as an immunohistochemical marker for Sertoli cells (6).
OGTTs were performed and compared to age-matched normal controls, no significant differences in blood glu-Smooth muscle alpha actin is known to be present in smooth muscle cells of blood vessels and in testicular cose levels were observed at all time points ( Fig. 1B) .
Removal of the graft-bearing kidneys in all mice was myoid cells (10) . Briefly, sections were heated in a microwave (15 min) in 0.01 M sodium citrate buffer (pH followed by a rapid return to the diabetic state. Furthermore, the mean cellular insulin contents of these grafts 6.0), incubated with 10% hydrogen peroxide to quench endogenous peroxidades, blocked with 20% normal se-were similar (25.5 ± 5.7 µg; n = 5) to the average cellular insulin content of the transplanted 500 mouse islets rum (15 min), and incubated with guinea pig anti-insulin (1:1000; Dako), anti-GATA-4 (1:50; Santa Cruz Bio-(30 µg). Histologically, the Sertoli cells were shown to be arranged in tubule structures with islets colocalized technology, Santa Cruz, CA), or anti-smooth muscle alpha actin (1:50; Dako, Carpinteria, CA) primary anti-and adjacent to the tubules (Fig. 2C) . The next series of experiments were designed to as-body for 30 min. Sections were then incubated with the appropriate biotinylated secondary antibody (20 min) sess whether the preengrafted Sertoli cells can function as an immunologically privileged site and thereby pro-followed by peroxidase-streptavidin with diaminobenzadine as the chromagen, thereby staining β-cells, Ser-tect allogeneic islets from rejection. When CBA/J mouse islets were transplanted in Balb/c mice with no preen-toli cells, and myoid cells brown. For double staining, days (Table 1) . Four mice, preimplanted with 4.8 ± 0.4 × 10 6 Sertoli cells, remained normoglycemic throughout the follow-up period and returned to a diabetic state only when the kidneys bearing the composite grafts were removed (Table 1) .
Histological analysis of graft-bearing kidneys in euglycemic recipients showed intact islets in close proximity to Sertoli cells (Fig. 2D ). Similar to the syngeneic grafts, the Sertoli cells were also arranged in tubules and the islets were directly adjacent to these tubules (Fig.  2D) . A layer of peritubular myoid cells was present along the basal edge of the tubules (Fig. 2E ) and a basement membrane was clearly localized to this region of the tubules (Fig. 2F ). In the grafts that had rejected, islets were either not detected or had lymphocytic infiltration ( Fig. 2G ). However, the Sertoli cells were still present and arranged in tubule structures similar to grafts in normoglycemic animals (Fig. 2H ).
DISCUSSION
The present study demonstrates that an immunoprivileged site can be created by preengrafting Sertoli cells and that this newly developed site subsequently protects allogeneic islets from rejection. Histological examination of the grafts revealed that Sertoli cells were arranged in tubules surrounded by peritubular myoid cells and a basement membrane. These tubule structures were similar to the morphological arrangement of seminiferous tubules in the testis, thereby demonstrating that Sertoli cell transplantation results in the formation of an immunoprivileged ectopic site comparable to the native testis. Moreover, the posttransplant formation of tubules implantation of an excessive mass of Sertoli cells results in hypoxic and nutrient-deprived conditions resulting in necrosis and inflammation and subsequent loss of Sertoli grafted Sertoli cells they were rejected within 16.3 ± 1.5 days (Table 1 ). In contrast, when CBA/J islets were cell mass. Ultimately, initially transplanting a higher mass of Sertoli cells actually results in less Sertoli cell transplanted adjacent to established Sertoli cell grafts, islet allograft survival was prolonged ( Table 1) . All mice engraftment and thereby a reduced ability to provide an immunoprivileged site for future islet allografts. receiving islet allografts implanted adjacent to the preengrated Sertoli cells achieved euglycemia within 2 days When syngeneic islets were implanted into this immunoprivileged ectopic site created by preengrafting posttransplant. When the immunoprivileged ectopic site was created by preengrafting 6.4 ± 0.3 × 10 6 Sertoli 5.7 ± 0.2 × 10 6 Sertoli cells, euglycemia was rapidly achieved and all recipients were glucose tolerant. These cells, mean islet allograft survival was prolonged but was not statistically different (32.4 ± 5.9 days; p = observations, taken together with the pre-and posttransplant cellular insulin contents of ϳ30 µg (i.e., 500 islets) 0.329) from islets alone. Reducing the number of preengrafted Sertoli cells to 4.8 ± 0.4 × 10 6 provided signifi-and 26 µg (harvest grafts), respectively, indicates that transplantation into a newly created immunoprivileged cant prolongation of islet allograft survival to 66.1 ± 9.8 
